CDK2 and neoplasm: Indisulam was first identified as a cell cycle blocker, inhibiting the activation of CDK2 and Cyclin E, decreasing the expression of Cyclin A, Cyclin B1 and CDK2 and arresting tumor cells in G1 phase [4, 5].